A2 Biotherapeutics Gene Fusion Patent US12599665B2

The USPTO issued Patent US12599665B2 to A2 Biotherapeutics, Inc. for gene fusion technology involving tBID polypeptides and steroid hormone receptor domains. The patent covers both the fusion protein compositions and methods of using them to induce apoptosis in cells. The filing date was August 12, 2021, under Application No. 18020728. Six claims were granted, with CPC classifications spanning therapeutic proteins (A61K, C07K) and cellular/gene therapy applications (C12N).

For affected parties, this patent grant establishes intellectual property protection that may restrict competitive development of similar apoptosis-inducing fusion proteins for cell control applications. Biotech and pharmaceutical companies developing gene-modified cell therapies involving tBID or steroid receptor domains should conduct freedom-to-operate analyses to assess potential infringement risks. Researchers and developers in cellular therapeutics should monitor related patent activity from A2 Biotherapeutics for licensing opportunities.